NEW YORK, Oct. 7 (GenomeWeb News) - The National Institute of Standards and Technology Advanced Technology Program approved Agilent Technologies to collaborate with Icoria on a drug-reaction bioinformatics project funded by a $11.7 million ATP grant, said Icoria in a statement today.
The ATP awarded the grant in support of its Target Assessment Technologies Suite, said the statement. The TATS project works to develop software and database technologies useful in identifying gene function and associated "leads for new pharmaceutical and chemical products rapidly, reliably, and efficiently," according to the ATP website.
Agilent takes the place of LION Bioscience, which withdrew from the project, said the statement.
Agilent will use its Agilent Synapsia Informatics Workbench, a data association framework for use in the study of "vast amounts" of genomic, proteomic, toxicologic, and drug efficacy data, the company said. The grant will fund an "enhancement" of the framework, and the two companies will work toward developing a commercializable software product, the company added.
"We look forward to working with Agilent in the ongoing development of important new technologies that enable scientists to gain greater insight into the development of safer and more effective medications," said Thomas J. Colatsky, Icoria vice president of Human Health Research, said in the statement.
Icoria has completed the first of three grant milestones, "the development, validation, and analysis of a coherent data set" concerning rat liver injury induced by acetaminophen, and the discovery of hepatoxicity biomarkers, said the company.